Cytochrome Therapeutics

SUMMARY

# Cytochrome Therapeutics ## Background and Rationale The mitochondrial dysfunction underlying Parkinson's disease represents one of the most compelling therapeutic targets in contemporary neurodegenerative disease research, with particular focus on the restoration of Complex I function within the electron transport chain. Cytochrome Therapeutics' clinical-stage investigation into novel compounds targeting mitochondrial respiratory capacity addresses a fundamental pathophysiological mechanism th

METHODOLOGY NOTES

**Phase 1: Pre-Clinical Validation (Months 1-6)** • Establish primary human dopaminergic neuron cultures from iPSC lines (n=12 PD patient-derived, n=6 healthy controls) • Characterize baseline Complex I activity using spectrophotometric assays and oxygen consumption rates • Treat cultures with lead CT compounds at concentrations 0.1-100 μM for 72h • Measure mitochondrial respiratory capacity, ATP production, and reactive oxygen species levels • Assess neuronal viability using lactate dehydrogenase release and caspase-3/7 activity **Phase 2: IND-Enabling Studies (Months 7-18)** • Conduct GLP toxicology studies in rodents (n=20/group) and non-human primates (n=6/group) • Perform pharmacokinetic analysis with blood sampling at 0.5, 1, 2, 4, 8, 24h post-dose • Complete genotoxicity battery including Ames test, chromosomal aberration, and micronucleus assays • Evaluate brain penetration using radiolabeled compound and autoradiography • File IND application with FDA including CMC data and c